{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T12:25:31Z","timestamp":1783081531225,"version":"3.54.6"},"reference-count":66,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T00:00:00Z","timestamp":1781136000000},"content-version":"vor","delay-in-days":10,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100017119","name":"The Wistar Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017119","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"NIH NCI","doi-asserted-by":"publisher","award":["T32 CA009171"],"award-info":[{"award-number":["T32 CA009171"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001340","name":"W. W. Smith Charitable Trust","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001340","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016255","name":"Inovio Pharmaceuticals Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016255","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Trends in Biotechnology"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.tibtech.2026.05.023","type":"journal-article","created":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T20:06:13Z","timestamp":1781899573000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Engineering single-dose plasmid DNA for sustained in vivo delivery of designer incretins"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2928-1120","authenticated-orcid":false,"given":"Ebony N.","family":"Gary","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yangcheng","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Casey E.","family":"Hojecki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas J.","family":"Tursi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wujuan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron R.","family":"Goldman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niklas","family":"Laenger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Tomirotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Suhail","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riya","family":"Sahai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob","family":"Oblander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinwei","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zi Jie","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiayan","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Humeau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesper","family":"Pallesen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth M.","family":"Parzych","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2232-8512","authenticated-orcid":false,"given":"David B.","family":"Weiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tibtech.2026.05.023_bb0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.peptides.2022.170749","article-title":"GLP-1 and GIP receptor signaling in beta cells \u2014 a review of receptor interactions and co-stimulation","volume":"151","author":"Mayendraraj","year":"2022","journal-title":"Peptides"},{"key":"10.1016\/j.tibtech.2026.05.023_bb0010","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1172\/JCI112855","article-title":"Insulinotropin: glucagon-like peptide I (7-37) co-encoded in the glucagon gene is a potent stimulator of insulin release in the perfused rat pancreas","volume":"79","author":"Mojsov","year":"1987","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.tibtech.2026.05.023_bb0015","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/j.molmet.2016.05.012","article-title":"Microbial regulation of GLP-1 and L-cell biology","volume":"5","author":"Greiner","year":"2016","journal-title":"Mol. Metab."},{"key":"10.1016\/j.tibtech.2026.05.023_bb0020","doi-asserted-by":"crossref","first-page":"7788","DOI":"10.1021\/jm900752a","article-title":"Eleven amino acid glucagon-like peptide-1 receptor agonists with antidiabetic activity","volume":"52","author":"Mapelli","year":"2009","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.tibtech.2026.05.023_bb0025","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s11154-014-9289-5","article-title":"Effects of GLP-1 on appetite and weight","volume":"15","author":"Shah","year":"2014","journal-title":"Rev. Endocr. Metab. Disord."},{"key":"10.1016\/j.tibtech.2026.05.023_bb0030","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1053\/j.gastro.2007.03.054","article-title":"Biology of incretins: GLP-1 and GIP","volume":"132","author":"Baggio","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.tibtech.2026.05.023_bb0035","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/j.2040-1124.2010.00022.x","article-title":"GIP and GLP-1, the two incretin hormones: similarities and differences","volume":"1","author":"Seino","year":"2010","journal-title":"J. Diabetes Investig."},{"key":"10.1016\/j.tibtech.2026.05.023_bb0040","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1038\/nrendo.2012.140","article-title":"GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus","volume":"8","author":"Meier","year":"2012","journal-title":"Nat. Rev. Endocrinol."},{"key":"10.1016\/j.tibtech.2026.05.023_bb0045","doi-asserted-by":"crossref","first-page":"15","DOI":"10.6065\/apem.2017.22.1.15","article-title":"Glucagon-like peptide-1 and glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes","volume":"22","author":"Lee","year":"2017","journal-title":"Ann. Pediatr. Endocrinol. Metab."},{"key":"10.1016\/j.tibtech.2026.05.023_bb0050","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.beem.2009.03.005","article-title":"Mechanisms underlying the rapid degradation and elimination of the incretin hormones GLP-1 and GIP","volume":"23","author":"Mentlein","year":"2009","journal-title":"Best Pract. Res. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.tibtech.2026.05.023_bb0055","doi-asserted-by":"crossref","first-page":"212","DOI":"10.5483\/BMBRep.2009.42.4.212","article-title":"Fc fusion to glucagon-like peptide-1 inhibits degradation by human DPP-IV, increasing its half-life in serum and inducing a potent activity for human GLP-1 receptor activation","volume":"42","author":"Kim","year":"2009","journal-title":"BMB Rep."},{"key":"10.1016\/j.tibtech.2026.05.023_bb0060","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.tcm.2021.12.008","article-title":"Semaglutide for the treatment of obesity","volume":"33","author":"Chao","year":"2023","journal-title":"Trends Cardiovasc. Med."},{"key":"10.1016\/j.tibtech.2026.05.023_bb0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2020.101102","article-title":"GLP-1 receptor agonists in the treatment of type 2 diabetes \u2013 state-of-the-art","volume":"46","author":"Nauck","year":"2021","journal-title":"Mol. Metab."},{"key":"10.1016\/j.tibtech.2026.05.023_bb0070","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.995646","article-title":"Real-world use of once-weekly semaglutide in patients with type 2 diabetes at an outpatient clinic in Spain","volume":"13","author":"Garcia de Lucas","year":"2022","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"10.1016\/j.tibtech.2026.05.023_bb0075","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1007\/s13300-018-0402-8","article-title":"Cost of achieving HbA1c treatment targets and weight loss responses with once-weekly semaglutide versus dulaglutide in the United States","volume":"9","author":"Wilkinson","year":"2018","journal-title":"Diabetes Ther."},{"key":"10.1016\/j.tibtech.2026.05.023_bb0080","doi-asserted-by":"crossref","first-page":"5886","DOI":"10.1038\/s41467-022-33309-6","article-title":"DNA-delivered antibody cocktail exhibits improved pharmacokinetics and confers prophylactic protection against SARS-CoV-2","volume":"13","author":"Parzych","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.tibtech.2026.05.023_bb0085","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1159\/000053993","article-title":"Plasmid DNA vaccines: investigation of integration into host cellular DNA following intramuscular injection in mice","volume":"43","author":"Ledwith","year":"2001","journal-title":"Intervirology"},{"key":"10.1016\/j.tibtech.2026.05.023_bb0090","doi-asserted-by":"crossref","first-page":"2801","DOI":"10.1016\/j.vaccine.2009.11.025","article-title":"FDA guidance on prophylactic DNA vaccines: analysis and recommendations","volume":"28","author":"Klinman","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.tibtech.2026.05.023_bb0095","doi-asserted-by":"crossref","first-page":"4150","DOI":"10.1038\/s41591-025-03969-0","article-title":"Safety and pharmacokinetics of SARS-CoV-2 DNA-encoded monoclonal antibodies in healthy adults: a phase 1 trial","volume":"31","author":"Tebas","year":"2025","journal-title":"Nat. Med."},{"key":"10.1016\/j.tibtech.2026.05.023_bb0100","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.jconrel.2011.09.072","article-title":"Efficient GLP-1 gene delivery using two-step transcription amplification plasmid system with a secretion signal peptide and arginine-grafted bioreducible polymer","volume":"157","author":"Kim","year":"2012","journal-title":"J. Control. Release"},{"key":"10.1016\/j.tibtech.2026.05.023_bb0105","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/j.ymthe.2005.03.039","article-title":"Glucagon-like peptide-1 plasmid construction and delivery for the treatment of type 2 diabetes","volume":"12","author":"Choi","year":"2005","journal-title":"Mol. Ther."},{"key":"10.1016\/j.tibtech.2026.05.023_bb0110","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1038\/gt.2011.25","article-title":"Effective and safe gene-based delivery of GLP-1 using chitosan\/plasmid-DNA therapeutic nanocomplexes in an animal model of type 2 diabetes","volume":"18","author":"Jean","year":"2011","journal-title":"Gene Ther."},{"key":"10.1016\/j.tibtech.2026.05.023_bb0115","doi-asserted-by":"crossref","first-page":"3404","DOI":"10.1007\/s11095-014-1430-3","article-title":"Oral delivery of glucagon like peptide-1 by a recombinant Lactococcus lactis","volume":"31","author":"Agarwal","year":"2014","journal-title":"Pharm. Res."},{"key":"10.1016\/j.tibtech.2026.05.023_bb0120","article-title":"Engineered MSCs secreting GLP-1 enhance \u03b2-cell survival and improve glycemic control in diabetic mice","volume":"795","author":"Huang","year":"2025","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.tibtech.2026.05.023_bb0125","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/s43856-025-00959-8","article-title":"Targeted in vivo gene integration of a secretion-enabled GLP-1 receptor agonist reverses diet-induced non-genetic obesity and pre-diabetes","volume":"5","author":"Hirose","year":"2025","journal-title":"Commun. Med. (Lond.)"},{"key":"10.1016\/j.tibtech.2026.05.023_bb0130","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1093\/infdis\/jiac016","article-title":"SARS-CoV-2 DNA vaccine INO-4800 induces durable immune responses capable of being boosted in a phase 1 open-label trial","volume":"225","author":"Kraynyak","year":"2022","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.tibtech.2026.05.023_bb0135","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1086\/515613","article-title":"First human trial of a DNA-based vaccine for treatment of human immunodeficiency virus type 1 infection: safety and host response","volume":"178","author":"MacGregor","year":"1998","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.tibtech.2026.05.023_bb0140","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1093\/infdis\/jit236","article-title":"Safety and comparative immunogenicity of an HIV-1 DNA vaccine in combination with plasmid interleukin 12 and impact of intramuscular electroporation for delivery","volume":"208","author":"Kalams","year":"2013","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.tibtech.2026.05.023_bb0145","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.137079","article-title":"Robust antibody and cellular responses induced by DNA-only vaccination for HIV","volume":"5","author":"De Rosa","year":"2020","journal-title":"JCI Insight"},{"key":"10.1016\/j.tibtech.2026.05.023_bb0150","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1158\/1940-6207.CAPR-22-0217","article-title":"Phase I trial of a therapeutic DNA vaccine for preventing hepatocellular carcinoma from chronic hepatitis C virus (HCV) infection","volume":"16","author":"Jacobson","year":"2023","journal-title":"Cancer Prev. Res. (Phila.)"},{"key":"10.1016\/j.tibtech.2026.05.023_bb0155","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003019","article-title":"Phase 1 study of safety, tolerability and immunogenicity of the human telomerase (hTERT)-encoded DNA plasmids INO-1400 and INO-1401 with or without IL-12 DNA plasmid INO-9012 in adult patients with solid tumors","volume":"9","author":"Vonderheide","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.tibtech.2026.05.023_bb0160","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1038\/s41467-025-56729-6","article-title":"DNA immunotherapy for recurrent respiratory papillomatosis (RRP): phase 1\/2 study assessing efficacy, safety, and immunogenicity of INO-3107","volume":"16","author":"Morrow","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.tibtech.2026.05.023_bb0165","doi-asserted-by":"crossref","first-page":"P426","DOI":"10.1186\/2051-1426-3-S2-P426","article-title":"Immunotherapy with VGX-3100 (HPV16 and HPV18 plasmids) + INO-9012 (DNA encoding IL-12) in human papillomavirus (HPV) associated head and neck squamous cell carcinoma (HNSCCa): interim safety and immunogenicity results","volume":"3","author":"Aggarwal","year":"2015","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.tibtech.2026.05.023_bb0170","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1016\/S0140-6736(15)00239-1","article-title":"Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2\/3: a randomised, double-blind, placebo-controlled phase 2b trial","volume":"386","author":"Trimble","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.tibtech.2026.05.023_bb0175","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0002517","article-title":"Heterosubtypic protection against pathogenic human and avian influenza viruses via in vivo electroporation of synthetic consensus DNA antigens","volume":"3","author":"Laddy","year":"2008","journal-title":"PLoS One"},{"key":"10.1016\/j.tibtech.2026.05.023_bb0180","doi-asserted-by":"crossref","first-page":"7173","DOI":"10.1016\/j.vaccine.2011.05.076","article-title":"Immunogenicity of a novel engineered HIV-1 clade C synthetic consensus-based envelope DNA vaccine","volume":"29","author":"Yan","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.tibtech.2026.05.023_bb0185","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1089\/hum.2018.102","article-title":"A synthetic micro-consensus DNA vaccine generates comprehensive influenza A H3N2 immunity and protects mice against lethal challenge by multiple H3N2 viruses","volume":"29","author":"Elliott","year":"2018","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.tibtech.2026.05.023_bb0190","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aac7462","article-title":"A synthetic consensus anti\u2013spike protein DNA vaccine induces protective immunity against Middle East respiratory syndrome coronavirus in nonhuman primates","volume":"7","author":"Muthumani","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.tibtech.2026.05.023_bb0195","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1632121","article-title":"Synthetic DNA co-immunization with vaccine-aligned common consensus nucleoprotein and hemagglutinin protects mice against lethal influenza infection with a single immunization","volume":"16","author":"Gary","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.tibtech.2026.05.023_bb0200","doi-asserted-by":"crossref","DOI":"10.1080\/22221751.2023.2294860","article-title":"In vivo delivery of engineered synthetic DNA-encoded SARS-CoV-2 monoclonal antibodies for pre-exposure prophylaxis in non-human primates","volume":"13","author":"Patel","year":"2024","journal-title":"Emerg. Microbes Infect."},{"key":"10.1016\/j.tibtech.2026.05.023_bb0205","article-title":"Mucosal chemokine adjuvant enhances synDNA vaccine-mediated responses to SARS-CoV-2 and provides heterologous protection in vivo","volume":"3","author":"Gary","year":"2022","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.tibtech.2026.05.023_bb0210","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1618297","article-title":"Fc-modification of anti-PcrV gene-encoded antibodies modulates complement-mediated killing of Pseudomonas aeruginosa","volume":"16","author":"Eisenhauer","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.tibtech.2026.05.023_bb0215","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.777395","article-title":"Lipidomic analysis reveals the protection mechanism of GLP-1 analogue dulaglutide on high-fat diet-induced chronic kidney disease in mice","volume":"12","author":"Yeung","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.tibtech.2026.05.023_bb0220","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2021.103382","article-title":"Recombinant human GLP-1 beinaglutide regulates lipid metabolism of adipose tissues in diet-induced obese mice","volume":"24","author":"Zhang","year":"2021","journal-title":"iScience"},{"key":"10.1016\/j.tibtech.2026.05.023_bb0225","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0002630","article-title":"Triacylglycerol fatty acid composition in diet-induced weight loss in subjects with abnormal glucose metabolism \u2013 the GENOBIN study","volume":"3","author":"Schwab","year":"2008","journal-title":"PLoS One"},{"key":"10.1016\/j.tibtech.2026.05.023_bb0230","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/S1525-0016(03)00036-4","article-title":"GLP-1 gene delivery for the treatment of type 2 diabetes","volume":"7","author":"Oh","year":"2003","journal-title":"Mol. Ther."},{"key":"10.1016\/j.tibtech.2026.05.023_bb0235","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.00242-21","article-title":"Synthetic DNA delivery of an optimized and engineered monoclonal antibody provides rapid and prolonged protection against experimental gonococcal infection","volume":"12","author":"Parzych","year":"2021","journal-title":"mBio"},{"key":"10.1016\/j.tibtech.2026.05.023_bb0240","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-022-18375-6","article-title":"Engineered DNA-encoded monoclonal antibodies targeting Plasmodium falciparum circumsporozoite protein confer single dose protection in a murine malaria challenge model","volume":"12","author":"Tursi","year":"2022","journal-title":"Sci. Rep."},{"key":"10.1016\/j.tibtech.2026.05.023_bb0245","doi-asserted-by":"crossref","first-page":"2626","DOI":"10.1016\/j.vaccine.2020.01.023","article-title":"CCR10 expression is required for the adjuvant activity of the mucosal chemokine CCL28 when delivered in the context of an HIV-1 Env DNA vaccine","volume":"38","author":"Gary","year":"2020","journal-title":"Vaccine"},{"key":"10.1016\/j.tibtech.2026.05.023_bb0250","doi-asserted-by":"crossref","first-page":"118","DOI":"10.4049\/jimmunol.2200056","article-title":"Improved durability to SARS-CoV-2 vaccine immunity following coimmunization with molecular adjuvant adenosine deaminase-1","volume":"209","author":"Cusimano","year":"2022","journal-title":"J. Immunol."},{"key":"10.1016\/j.tibtech.2026.05.023_bb0255","doi-asserted-by":"crossref","first-page":"3821","DOI":"10.1016\/j.vaccine.2020.03.047","article-title":"Adenosine deaminase-1 enhances germinal center formation and functional antibody responses to HIV-1 Envelope DNA and protein vaccines","volume":"38","author":"Gary","year":"2020","journal-title":"Vaccine"},{"key":"10.1016\/j.tibtech.2026.05.023_bb0260","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1138609","article-title":"Adenosine deaminase augments SARS-CoV-2 specific cellular and humoral responses in aged mouse models of immunization and challenge","volume":"14","author":"Gary","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.tibtech.2026.05.023_bb0265","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2020.100689","article-title":"Safety and immunogenicity of INO-4800 DNA vaccine against SARS-CoV-2: a preliminary report of an open-label, Phase 1 clinical trial","volume":"31","author":"Tebas","year":"2021","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.tibtech.2026.05.023_bb0270","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1038\/s41591-024-02894-y","article-title":"Personalized neoantigen vaccine and pembrolizumab in advanced hepatocellular carcinoma: a phase 1\/2 trial","volume":"30","author":"Yarchoan","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.tibtech.2026.05.023_bb0275","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/S2213-2600(22)00180-1","article-title":"Efficacy and safety of intramuscular administration of tixagevimab-cilgavimab for early outpatient treatment of COVID-19 (TACKLE): a phase 3, randomised, double-blind, placebo-controlled trial","volume":"10","author":"Montgomery","year":"2022","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.tibtech.2026.05.023_bb0280","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.tibtech.2026.05.023_bb0285","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide once weekly for the treatment of obesity","volume":"387","author":"Jastreboff","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.tibtech.2026.05.023_bb0290","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/S0140-6736(23)01200-X","article-title":"Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial","volume":"402","author":"Garvey","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.tibtech.2026.05.023_bb0295","doi-asserted-by":"crossref","first-page":"124","DOI":"10.2337\/diabetes.52.1.124","article-title":"Glucagon-like peptide 1 induces pancreatic \u03b2-cell proliferation via transactivation of the epidermal growth factor receptor","volume":"52","author":"Buteau","year":"2003","journal-title":"Diabetes"},{"key":"10.1016\/j.tibtech.2026.05.023_bb0300","doi-asserted-by":"crossref","first-page":"2851","DOI":"10.2337\/db09-0685","article-title":"Glucagon-like peptide-1 agonists protect pancreatic \u03b2-cells from lipotoxic endoplasmic reticulum stress through upregulation of BiP and JunB","volume":"58","author":"Cunha","year":"2009","journal-title":"Diabetes"},{"key":"10.1016\/j.tibtech.2026.05.023_bb0305","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.cmet.2006.01.004","article-title":"The biology of incretin hormones","volume":"3","author":"Drucker","year":"2006","journal-title":"Cell Metab."},{"key":"10.1016\/j.tibtech.2026.05.023_bb0310","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1111\/joim.12388","article-title":"Impaired incretin effect is an early sign of glucose dysmetabolism in nondiabetic patients with psoriasis","volume":"278","author":"Gyldenl\u00f8ve","year":"2015","journal-title":"J. Intern. Med."},{"key":"10.1016\/j.tibtech.2026.05.023_bb0315","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2021.100979","article-title":"GLP-1 based therapies and disease course of inflammatory bowel disease","volume":"37","author":"Villumsen","year":"2021","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.tibtech.2026.05.023_bb0320","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1158\/2159-8290.CD-20-0329","article-title":"Changes in aged fibroblast lipid metabolism induce age-dependent melanoma cell resistance to targeted therapy via the fatty acid transporter FATP2","volume":"10","author":"Alicea","year":"2020","journal-title":"Cancer Discov."},{"key":"10.1016\/j.tibtech.2026.05.023_bb0325","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1038\/s41586-021-03819-2","article-title":"Highly accurate protein structure prediction with AlphaFold","volume":"596","author":"Jumper","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.tibtech.2026.05.023_bb0330","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/s41586-024-07487-w","article-title":"Accurate structure prediction of biomolecular interactions with AlphaFold 3","volume":"630","author":"Abramson","year":"2024","journal-title":"Nature"}],"container-title":["Trends in Biotechnology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167779926002362?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167779926002362?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T12:09:14Z","timestamp":1783080554000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167779926002362"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":66,"alternative-id":["S0167779926002362"],"URL":"https:\/\/doi.org\/10.1016\/j.tibtech.2026.05.023","relation":{},"ISSN":["0167-7799"],"issn-type":[{"value":"0167-7799","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Engineering single-dose plasmid DNA for sustained in vivo delivery of designer incretins","name":"articletitle","label":"Article Title"},{"value":"Trends in Biotechnology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tibtech.2026.05.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}